Advanced glycation end product receptor (RAGE)

The Advanced glycation end product receptor (RAGE) is a multi-ligand transmembrane protein belonging to the immunoglobulin superfamily that acts as a pattern recognition receptor [1]. It is primarily characterized by its ability to bind advanced glycation end products (AGEs), which are non-enzymatically glycated proteins or lipids that accumulate during aging and in metabolic disorders like diabetes [2]. Beyond AGEs, RAGE interacts with a diverse array of ligands, including S100/calgranulins, high mobility group box 1 (HMGB1), and amyloid-beta peptides, making it a central hub for inflammatory signaling [3]. Upon ligand binding, RAGE initiates intracellular signaling pathways, most notably the activation of nuclear factor-kappa B (NF-κB), which leads to the sustained expression of pro-inflammatory cytokines and the generation of reactive oxygen species [4]. This signaling cascade is heavily implicated in the development of diabetic complications, atherosclerosis, neurodegeneration, and certain cancers [2, 3]. Consequently, RAGE is considered a significant therapeutic target, with drug development efforts focusing on small-molecule antagonists and soluble decoy receptors to interrupt the pro-inflammatory cycle [5]. Sources: [1] UniProt Q15109; [2] StatPearls: Advanced Glycation End Products; [3] PMID: 30107159; [4] PMID: 22461011; [5] ClinicalTrials.gov (Azeliragon).

Other names

AGERReceptor for advanced glycation end productsRAGE receptorAdvanced glycosylation end product-specific receptor

Competitive antagonism of the RAGE receptor to prevent the binding of ligands such as AGEs, HMGB1, and S100 proteins, thereby inhibiting downstream pro-inflammatory signaling pathways including NF-κB activation and the production of reactive oxygen species [3, 4].